Cargando…
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
Osimertinib, a mutant-specific third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is emerging as the preferred first-line of treatment for EGFR-mutant lung cancer. However, osimertinib resistance inevitably develops among patients treated with the drug. The mod...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363540/ https://www.ncbi.nlm.nih.gov/pubmed/35943592 http://dx.doi.org/10.1007/s12672-022-00537-7 |